Highest-materiality recent filing
Clearside Biomedical bankruptcy court approves sale process; Health Ocean Limited as stalking horse
Court approved bidding procedures on Dec 19, 2025; Health Ocean Limited designated as stalking horse bidder.
Clearside Biomedical files Form 25 to complete Nasdaq delisting after Chapter 11 bankruptcy
Filed Form 25 on Dec 8, 2025 to delist from Nasdaq and deregister under Section 12(b); effective no earlier than Dec 18, 2025.
Clearside Biomedical files for Chapter 11 bankruptcy; Nasdaq delisting effective Dec 1
Filed voluntary Chapter 11 petition on Nov 23, 2025 in Delaware (Case No. 25-12109).
Clearside Biomedical regains Nasdaq minimum bid price compliance via reverse split
Received Nasdaq Panel letter on Oct 6, 2025 confirming compliance with Minimum Bid Price Requirement.
Clearside Biomedical announces 1-for-15 reverse stock split, authorized shares reduced to 26.7M
Reverse stock split at 1-for-15 ratio; effective 5:00 p.m. ET on Sept 12, 2025.
Clearside Biomedical files 1-for-15 reverse stock split, reduces authorized shares to 26.7M
Reverse stock split effective September 12, 2025 at 5:00 p.m. ET; split-adjusted trading begins September 15, 2025.
Clearside Biomedical receives additional $3M from Healthcare Royalty; reduces royalty cap
Company entered Omnibus Amendment with Healthcare Royalty Partners; received $3.0M for remaining SCS Microinjector assets.
Clearside Biomedical gets Nasdaq MVLS deficiency notice; stockholders approve reverse stock split
Received Nasdaq notice on Aug 28, 2025 for non-compliance with $50M MVLS requirement for continued listing on Global Market.
Clearside receives Nasdaq delisting notice; Chairperson Gibney resigns, Thorp succeeds
Nasdaq notified Clearside on Aug 11, 2025 that its common stock is subject to delisting due to bid price below $1.00 for 30 consecutive business days.
Clearside explores strategic alternatives; all employees terminated, R&D paused
All employees, including CEO, CFO, CMO, terminated effective July 18, 2025, transition to consulting roles.
Clearside Biomedical shareholders approve doubling authorized common stock to 400M shares
Shareholders approved amendment to increase authorized common shares from 200M to 400M; 38.8M for, 10.3M against, 0.6M abstain.
Clearside Biomedical Q1 net loss narrows to $8.2M; FDA agrees on Phase 3 plan for CLS-AX in wet AMD
Net loss $8.2M ($0.11/sh) vs $11.8M ($0.17) YoY; license revenue $2.3M (up from $0.2M) on Arctic Vision milestone.
Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD
Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).
Clearside Biomedical receives Nasdaq minimum bid price deficiency notice
Notice received Feb 7, 2025; stock below $1.00 for 30 consecutive business days.
Clearside updates corporate presentation; specifics in slides 31-37 not visible in filing text
Filing furnishes updated investor deck for analyst and investor meetings.
Clearside Q3 2024 net loss $7.7M; ODYSSEY Phase 2b wet AMD trial hits all endpoints
Net loss of $7.7M ($0.10 per share) vs. $9.3M ($0.15) in Q3 2023; revenue $1.0M, up from $0.9M.
Clearside reports positive ODYSSEY Phase 2b results for CLS-AX in wet AMD; all endpoints met
ODYSSEY Phase 2b trial of suprachoroidal CLS-AX achieved primary and secondary outcomes; stable BCVA and CSRT through 36 weeks.
Clearside Biomedical Q2 net loss narrows to $7.6M; Phase 2b wet AMD trial on track for late Q3 data
Net loss of $7.6M ($0.10/sh) vs $9.1M ($0.15/sh) in Q2 2023; license revenue $90,000.
Clearside Biomedical holds KOL webinar on suprachoroidal delivery; no new financial data
Company hosted virtual Suprachoroidal Delivery KOL Webinar on July 24, 2024.
Clearside Biomedical stockholders elect all three director nominees, approve say-on-pay, ratify E&Y
Directors Croarkin, Humphries, and Hutson elected with ~30M votes for each; no nominee withheld.
Clearside reports Q1 net loss $11.8M, $0.17/sh; cash $35.4M; ODYSSEY topline due Q3 2024
Net loss $11.8M ($0.17/sh) vs $9.3M ($0.15) Q1 2023; revenue $230K up from $4K.
Clearside Biomedical appoints Anthony S. Gibney to its Board of Directors
Mr. Gibney appointed as a Class III director effective April 15, 2024; term runs through 2025 annual meeting.
Clearside Biomedical Q4 2023 net loss narrows to $4.8M; cash runway to Q3 2025
Net loss Q4 2023 of $4.8M ($0.08/shr) improved from $9.7M loss ($0.16/shr) in Q4 2022.
Clearside Biomedical prices $15M registered direct offering of 11.1M shares and warrants
Gross proceeds ~$15M from sale of 11,111,111 shares and warrants at $1.35 per unit.
Sublicense percentage reduced from low double digits to high single digits for fees received from sublicensees.
Clearside Biomedical waives $12.5M milestone payment, releases escrow to HCR
Subsidiary Clearside Royalty waived all rights to $12.5M milestone payment tied to XIPERE sales.
Clearside Q3 net loss $9.3M; inks BioCryst licensing deal for DME with $5M upfront
Net loss of $9.3M ($0.15/share) vs $7.8M loss ($0.13/share) in Q3 2022.
Clearside Biomedical licenses SCS Microinjector to BioCryst for avoralstat in DME
Clearside granted BioCryst exclusive worldwide license to use SCS Microinjector for avoralstat in diabetic macular edema.
Clearside Biomedical receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on Sept 27, 2023 for non-compliance with minimum bid price rule.
Clearside Q2 net loss $9.1M; Phase 2b ODYSSEY enrollment underway, topline Q3 2024
Net loss $9.1M ($0.15/share) vs $7.8M ($0.13) prior year; cash $35.0M, operations funded into Q3 2024.
Clearside Biomedical shareholders re-elect all three director nominees
Jeffrey L. Edwards, Clay B. Thorp, and Benjamin R. Yerxa re-elected with 21.0M, 21.0M, and 22.8M votes for, respectively.
Clearside terminates Cowen ATM facility, enters new up to $50M at-the-market equity deal with Cantor
Terminated prior Cowen Sales Agreement effective May 12, 2023; $35.8M net raised from ~19M shares since 2017.
Clearside Biomedical Q1 net loss $9.3M; Phase 2b ODYSSEY trial to open Q2 2023
Net loss of $9.3M ($0.15 per share) vs $7.6M ($0.13) in Q1 2022.
Clearside Biomedical announces plans for Phase 2b ODYSSEY trial of CLS-AX in wet AMD
Phase 2b trial ODYSSEY to enroll 60 patients with wet AMD; 2:1 randomization CLS-AX vs aflibercept.
Clearside Biomedical reports Q4 net loss of $9.7M; Phase 2b wet AMD trial on track for Q2 2023
Q4 net loss $9.7M ($0.16/share) vs net income $18.7M ($0.31/share) in Q4 2021 on lower license revenue.
Clearside Biomedical CMO Thomas Ciulla resigns, becomes advisor under consulting agreement
Thomas Ciulla resigned as CMO and CDO effective Feb 17, 2023; will serve as Chairman of Scientific Advisory Board and Chief Medical Advisor – Retina.
Clearside Biomedical CMO/CVO Thomas Ciulla resigns effective Feb 17; will serve as advisor
Thomas Ciulla resigns as Chief Medical Officer and Chief Development Officer of Clearside Biomedical.
67% of extension participants (8/12) went ≥6 months without additional treatment; 50% went >6 months.
Clearside reports Q3 net loss of $7.8M; OASIS trial shows positive durability for CLS-AX
Q3 2022 net loss of $7.8M ($0.13/share) vs $4.9M loss in Q3 2021; revenue fell to $0.3M from $3.1M.
Clearside reports Q2 loss of $7.8M, secures $65M non-dilutive financing, OASIS data due Nov
Net loss $7.8M ($0.13/shr) vs $6.1M ($0.11/shr) in Q2 2021; license revenue $384K down from $780K.
Clearside Biomedical enters royalty financing with HealthCare Royalty for up to $65M
Upfront cash of $32.5M; additional $12.5M escrow tied to XIPERE sales milestone, plus up to $20M second milestone.
Clearside Biomedical shareholders approve doubling authorized common stock to 200M shares
Shareholders approved amendment to increase authorized common shares from 100M to 200M (32.6M for, 4.4M against, 6.0M abstain).
Clearside Biomedical Q1 2022 net loss $7.6M; CLS-AX cohort 4 enrolling
Net loss of $7.6M ($0.13 per share) vs $7.4M ($0.13) in Q1 2021; revenue $347K vs $34K.
Clearside Biomedical Q4 2021 net income $18.7M on XIPERE milestones; CLS-AX trial advances
Q4 2021 license revenue $25.7M (vs $11K in Q4 2020) from $20M in XIPERE milestones; net income $18.7M ($0.31/sh) vs net loss $7.1M.
Clearside Biomedical appoints Benjamin Yerxa, Ph.D. to Board of Directors
Dr. Yerxa, CEO of Foundation Fighting Blindness and Clearside co-founder, appointed effective March 2, 2022.
Cohort 2 (0.1 mg CLS-AX, n=5) well-tolerated: no serious adverse events, no treatment-related AEs, no vitreous dispersion.
Clearside Biomedical reports Q3 loss of $0.08/share; XIPERE approval triggers $19M milestones
XIPERE (triamcinolone acetonide) approved by FDA in Oct 2021 for macular edema associated with uveitis; first product for suprachoroidal injection.
XIPERE (triamcinolone acetonide injectable suspension) is the first FDA-approved therapy for suprachoroidal injection.
Clearside reports Q2 2021 net loss $6.1M; OASIS Cohort 2 underway; XIPERE PDUFA Oct 30
Net loss of $6.1M ($0.11/share) vs $5.8M ($0.13/share) in Q2 2020.
On April 15, 2024, the Board of Directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Anthony S. Gibney to serve as a director of the Company.
Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17, 2023
On February 2, 2023, Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17. 2023
the board of directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Benjamin Yerxa to serve as a director of the Company, effective immediately.
Max materiality 0.95 · Median 0.65 · Most common event other_material